UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Gen-Probe Incorporated

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)		001-31279 (Commission File Number)		33-0044608 (I.R.S. Employer Identification No.)

10210 Genetic Center Drive San Diego, CA (Address of Principal Executive Offices)		92121 (Zip Code)

(858) 410-8000
(Registrant’s telephone number, including area code)

     Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02.		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     The following disclosure is provided pursuant to subsection (b) of Item 5.02 of Form 8-K.

     On September 16, 2009, Raymond V. Dittamore informed Gen-Probe Incorporated (the “Company”) that he was resigning from the Company’s board of directors (the “Board”) effective as of September 17, 2009. Mr. Dittamore has served as a member of the Board since August 2002.

Item 8.01.		Other Events.

     On September 17, 2009, the Board appointed John C. Martin, Ph.D. to serve as a member of the Audit Committee of the Board. Dr. Martin was appointed to the Audit Committee to fill the vacancy created on that committee by Mr. Dittamore’s resignation from the Board. Dr. Martin has served as a member of the Company’s Board since September 2007. Dr. Martin currently serves as the Chairman and Chief Executive Officer of Gilead Sciences, Inc.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.